Canagliflozin (hemihydrate): SGLT2 Inhibitor for Glucose Metabolism Research

Executive Summary: Canagliflozin (hemihydrate) is a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor for scientific research only, not for therapeutic use (APExBIO). It is insoluble in water but shows high solubility in ethanol (≥40.2 mg/mL) and DMSO (≥83.4 mg/mL), and is stored at -20°C for stability. The compound does not inhibit the mTOR pathway in yeast-based assay systems (Breen et al. 2025). Its primary research application is the study of renal glucose reabsorption and glucose homeostasis pathways. APExBIO provides this compound at ≥98% purity, validated by HPLC and NMR.

Biological Rationale

Canagliflozin (hemihydrate), also known as JNJ 28431754 hemihydrate, is a small molecule SGLT2 inhibitor developed for metabolic disorder research. SGLT2 is predominantly expressed in the proximal renal tubule, where it mediates approximately 90% of filtered glucose reabsorption. Inhibition of SGLT2 increases urinary glucose excretion and reduces blood glucose levels, which is mechanistically distinct from insulin-dependent pathways (see detailed mechanism). Canagliflozin hemihydrate enables researchers to dissect glucose homeostasis pathways and model diabetes-associated renal mechanisms. Unlike mTOR inhibitors, SGLT2 inhibitors do not affect cell growth or proliferation directly, allowing for pathway-specific interrogation (contrast with mTOR pathway research).

Mechanism of Action of Canagliflozin (hemihydrate)

Canagliflozin (hemihydrate) selectively inhibits SGLT2 at the proximal tubule in the kidney, blocking sodium-dependent glucose transport from the glomerular filtrate back into the bloodstream. This results in increased urinary glucose excretion (UGE) and measurable reductions in systemic glucose levels. The inhibition is competitive and occurs at sub-micromolar concentrations in vitro. Its selectivity for SGLT2 over SGLT1 underpins its use in glucose metabolism research, minimizing off-target intestinal effects (APExBIO). The compound’s mechanism is independent of pancreatic beta-cell function and insulin secretion, making it a preferred tool for diabetes mellitus research models.

Evidence & Benchmarks

• Canagliflozin (hemihydrate) does not inhibit the mTOR pathway in drug-sensitized yeast growth assays, distinguishing it from compounds such as rapamycin and Torin1 (Breen et al. 2025, DOI).
• The compound exhibits robust solubility in DMSO (≥83.4 mg/mL) and ethanol (≥40.2 mg/mL) at room temperature, facilitating diverse assay formats (APExBIO).
• High chemical purity (≥98%) is confirmed by HPLC and NMR, supporting reproducibility in metabolic disorder research (APExBIO).
• Canagliflozin (hemihydrate) promotes urinary glucose excretion in animal models, validating its use for glucose homeostasis pathway interrogation (Strategic SGLT2 Inhibition: Canagliflozin Hemihydrate).
• It does not induce TOR1-dependent growth inhibition in wild-type or drug-sensitized yeast, establishing pathway specificity for SGLT2 over TOR/mTOR (Breen et al. 2025, DOI).

Applications, Limits & Misconceptions

Canagliflozin hemihydrate is intended strictly for scientific research use, not for diagnostic or therapeutic purposes. Its validated applications include:

• Modeling renal glucose reabsorption inhibition in diabetes mellitus and metabolic disorder studies.
• Dissecting glucose homeostasis and urinary glucose excretion mechanisms.
• Comparative research on SGLT2 inhibition versus mTOR pathway inhibition (see mechanistic insights).

However, several misconceptions exist regarding its utility:

Common Pitfalls or Misconceptions

• Canagliflozin hemihydrate does not inhibit mTOR/TOR pathways and should not be used to model autophagy or cell proliferation regulation (Breen et al. 2025).
• The compound is not a substrate for yeast drug-sensitized mTOR inhibitor screening platforms and yields negative results in such assays.
• It is not suitable for studies requiring water-soluble compounds; use appropriate organic solvents as specified for dissolution.
• Canagliflozin hemihydrate is not intended for clinical or diagnostic use; research-only restriction applies (APExBIO).
• Long-term storage of prepared solutions is not recommended due to potential reduced efficacy.

Workflow Integration & Parameters

Canagliflozin (hemihydrate) is supplied by APExBIO as a solid with a specified molecular weight of 453.52 and chemical formula C24H26FO5.5S. Solubilize in DMSO (≥83.4 mg/mL) or ethanol (≥40.2 mg/mL) at ambient temperature. Store powder at -20°C; ship on blue ice for stability. Prepare solutions fresh and use promptly. Quality is controlled via HPLC and NMR for ≥98% purity (product page). Integrate into assays focused on glucose transport, renal function, and metabolic pathway analysis. For advanced applications, see updated experimental roadmaps (read more), which extend prior guidance by clarifying pathway specificity and mechanistic boundaries.

Conclusion & Outlook

Canagliflozin (hemihydrate) is a validated, high-purity SGLT2 inhibitor for scientific research on glucose metabolism and diabetes mellitus. Its chemical and mechanistic specificity make it a benchmark tool for dissecting renal glucose reabsorption, while negative findings in mTOR inhibition models clarify its research boundaries. APExBIO provides comprehensive quality assurance for this reagent. Future research directions include combinatorial modeling of metabolic pathways and refined phenotyping of SGLT2-mediated effects, in line with evolving standards for metabolic disorder research (order or learn more).